Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Daniel Barreto de Melo*, Rosa Maria Rodrigues Pereira, Bruno Sini, Débora Levy, Lilian Takayama, Cristina Maria Kokron, Ana Karolina Berselli Marinho, Octavio Grecco, Jorge Elias Kalil Filho and Myrthes Toledo Barros

DOI: 10.2174/1871530323666230822100031

DownloadDownload PDF Flyer Cite As
Bone Mineral Density is Related to CD4+ T Cell Counts and Muscle Mass is Associated with B Cells in Common Variable Immunodeficiency Patients

Page: [242 - 254] Pages: 13

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Background: Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by chronic/recurrent respiratory infections, bronchiectasis, autoimmunity, inflammatory, gastrointestinal diseases and malignancies associated with a chronic inflammatory state and increased risk of osteoporosis and muscle loss.

Aim: The aim of this study was to evaluate bone mineral density (BMD), body composition and their relationship with lymphocyte subpopulations in CVID patients.

Methods: Dual-energy X-ray absorptiometry was performed to assess BMD, lean mass, and fat mass in CVID patients. Peripheral blood CD4+, CD8+, and CD19+ cells were measured using flow cytometry.

Results: Thirty-three patients (37.3 ± 10.8 years old) were examined. Although only 11.8% of the individuals were malnourished (BMI <18.5 kg/m2), 27.7% of them had low skeletal muscle mass index (SMI), and 57.6% of them had low BMD. Patients with osteopenia/osteoporosis presented lower weight (p = 0.007), lean mass (p = 0.011), appendicular lean mass (p = 0.011), SMI (p = 0.017), and CD4+ count (p = 0.030). Regression models showed a positive association between CD4+ count and bone/muscle parameters, whereas CD19+ B cell count was only associated with muscle variables. Analysis of ROC curves indicated a cutoff value of CD4+ count (657 cells/mm3; AUC: 0.71, 95% CI 0.52-0.90) which was related to low BMD. Weight (p = 0.004), lean mass (p = 0.027), appendicular lean mass (p = 0.022), SMI (p = 0.029), total bone mineral content (p = 0.005), lumbar (p = 0.005), femoral neck (p = 0.035), and total hip BMD (p<0.001) were found to be lower in patients with CD4+ count below the cutoff.

Conclusion: CVID patients presented with low BMD, which was associated with CD4+ count. Moreover, low muscle parameters were correlated with B cell count.

Keywords: Bone mineral density, osteoporosis, lean mass, CD4+ T cells, B cells, common variable immunodeficiency.

Graphical Abstract

[1]
Bonilla, F.A.; Barlan, I.; Chapel, H.; Costa-Carvalho, B.T.; Cunningham-Rundles, C.; de la Morena, M.T.; Espinosa-Rosales, F.J.; Hammarström, L.; Nonoyama, S.; Quinti, I.; Routes, J.M.; Tang, M.L.K.; Warnatz, K. International consensus document (ICON): Common variable immunodeficiency disorders. J. Allergy Clin. Immunol. Pract., 2016, 4(1), 38-59.
[http://dx.doi.org/10.1016/j.jaip.2015.07.025] [PMID: 26563668]
[2]
Ameratunga, R.; Allan, C.; Woon, S.T. Defining common variable immunodeficiency disorders in 2020. Immunol. Allergy Clin. North Am., 2020, 40(3), 403-420.
[http://dx.doi.org/10.1016/j.iac.2020.03.001] [PMID: 32654689]
[3]
Lee, T.K.; Gereige, J.D.; Maglione, P.J. State-of-the-art diagnostic evaluation of common variable immunodeficiency. Ann. Allergy Asthma Immunol., 2021, 127(1), 19-27.
[http://dx.doi.org/10.1016/j.anai.2021.03.005] [PMID: 33716149]
[4]
Cunningham-Rundles, C.; Bodian, C. Common variable immunodeficiency: Clinical and immunological features of 248 patients. Clin. Immunol., 1999, 92(1), 34-48.
[http://dx.doi.org/10.1006/clim.1999.4725] [PMID: 10413651]
[5]
Yesillik, S.; Agrawal, S.; Gollapudi, S.V.; Gupta, S. Phenotypic analysis of CD4+ Treg, CD8+ Treg, and breg cells in adult common variable immunodeficiency patients. Int. Arch. Allergy Immunol., 2019, 180(2), 150-158.
[http://dx.doi.org/10.1159/000501457] [PMID: 31284281]
[6]
Resnick, E.S.; Moshier, E.L.; Godbold, J.H.; Cunningham-Rundles, C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood, 2012, 119(7), 1650-1657.
[http://dx.doi.org/10.1182/blood-2011-09-377945] [PMID: 22180439]
[7]
Szczawińska-Popłonyk, A.; Ta̧polska-Jóźwiak, K.; Schwartzmann, E.; Popłonyk, N. Immune dysregulation in pediatric common variable immunodeficiency: Implications for the diagnostic approach. Front Pediatr., 2022, 10, 855200.
[http://dx.doi.org/10.3389/fped.2022.855200] [PMID: 35402361]
[8]
Baris, S.; Ozen, A.; Ercan, H.; Karakoc-Aydiner, E.; Cagan, H.; Ozdemir, C.; Barlan, M.; Bahceciler, N.N.; Barlan, I.B. Osteoporosis: An ignored complication of CVID. Pediatr. Allergy Immunol., 2011, 22(7), 676-683.
[http://dx.doi.org/10.1111/j.1399-3038.2011.01187.x] [PMID: 21645119]
[9]
Ayteki̇n, G.; Çölkesen, F.; Yildiz, E.; Arslan, Ş.; Çalişkaner, A.Z. Bone metabolism alterations in patients with common variable immune deficiency: A retrospective cohort study. Asthma Allergy Immunology, 2020, 18(2), 66-72.
[http://dx.doi.org/10.21911/aai.501]
[10]
Mohebbi, A.; Azizi, G.; Tavakolinia, N.; Abbasi, F.; Sayarifard, F.; Karimipour, M.; Kiaee, F.; Yazdani, R.; Ebrahimi, S.S.; Ebrahimi, M.; Rafiemanesh, H.; Tafaroji, J.; Ziaee, V.; Abolhassani, H.; Aghamohammadi, A. Comparison of bone mineral density in common variable immunodeficiency and x-linked agammaglobulinaemia patients. Endocr. Metab. Immune Disord. Drug Targets, 2017, 17(2), 134-140.
[PMID: 28606051]
[11]
Briot, K.; Geusens, P. Em Bultink, I.; Lems, W.F.; Roux, C. Inflammatory diseases and bone fragility. Osteoporos. Int., 2017, 28(12), 3301-3314.
[http://dx.doi.org/10.1007/s00198-017-4189-7] [PMID: 28916915]
[12]
Li, Y.; Toraldo, G.; Li, A.; Yang, X.; Zhang, H.; Qian, W.P.; Weitzmann, M.N. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 2007, 109(9), 3839-3848.
[http://dx.doi.org/10.1182/blood-2006-07-037994] [PMID: 17202317]
[13]
Sowerwine, K.J.; Shaw, P.A.; Gu, W.; Ling, J.C.; Collins, M.T.; Darnell, D.N.; Anderson, V.L.; Davis, J.; Hsu, A.; Welch, P.; Puck, J.M.; Holland, S.M.; Freeman, A.F. Bone density and fractures in autosomal dominant hyper IgE syndrome. J. Clin. Immunol., 2014, 34(2), 260-264.
[http://dx.doi.org/10.1007/s10875-013-9982-2] [PMID: 24402620]
[14]
Lopez-Granados, E.; Temmerman, S.T.; Wu, L.; Reynolds, J.C.; Follmann, D.; Liu, S.; Nelson, D.L.; Rauch, F.; Jain, A. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc. Natl. Acad. Sci., 2007, 104(12), 5056-5061.
[http://dx.doi.org/10.1073/pnas.0605715104] [PMID: 17360404]
[15]
Cascio, A.; Colomba, C.; Di Carlo, P.; Serra, N.; Lo Re, G.; Gambino, A.; Lo Casto, A.; Guglielmi, G.; Veronese, N.; Lagalla, R.; Sergi, C. Low bone mineral density in HIV-positive young Italians and migrants. PLoS One, 2020, 15(9), e0237984.
[http://dx.doi.org/10.1371/journal.pone.0237984] [PMID: 32881882]
[16]
Pramukti, I.; Lindayani, L.; Chen, Y.C.; Yeh, C.Y.; Tai, T.W.; Fetzer, S.; Ko, N.Y. Bone fracture among people living with HIV: A systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS One, 2020, 15(6), e0233501.
[http://dx.doi.org/10.1371/journal.pone.0233501] [PMID: 32497105]
[17]
Goh, S.S.L.; Lai, P.S.M.; Tan, A.T.B.; Ponnampalavanar, S. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors: Supplementary presentation. Osteoporos. Int., 2018, 29(7), 1683.
[http://dx.doi.org/10.1007/s00198-018-4379-y] [PMID: 29737369]
[18]
Berbers, R.M.; van der Wal, M.M.; van Montfrans, J.M.; Ellerbroek, P.M.; Dalm, V.A.S.H.; van Hagen, P.M.; Leavis, H.L.; van Wijk, F. Chronically activated T-cells retain their inflammatory properties in common variable immunodeficiency. J. Clin. Immunol., 2021, 41(7), 1621-1632.
[http://dx.doi.org/10.1007/s10875-021-01084-6] [PMID: 34247288]
[19]
Litzman, J.; Nechvatalova, J.; Xu, J.; Ticha, O.; Vlkova, M.; Hel, Z. Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia. Clin. Exp. Immunol., 2012, 170(3), 321-332.
[http://dx.doi.org/10.1111/j.1365-2249.2012.04655.x] [PMID: 23121673]
[20]
World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Heal. Organ. -. Tech. Rep. Ser., 2000, 894, i-xii, 1-253.
[21]
Eastell, R.; Schini, M. Prevention and management of osteoporosis. Med., 2021, 49, 572-577.
[22]
Leib, E.S.; Lewiecki, E.M.; Binkley, N.; Hamdy, R.C. Official positions of the international society for clinical densitometry. South. Med. J., 2004, 97(1), 107-110.
[http://dx.doi.org/10.1097/00007611-200401000-00029] [PMID: 14746436]
[23]
Baumgartner, R.N.; Koehler, K.M.; Gallagher, D.; Romero, L.; Heymsfield, S.B.; Ross, R.R.; Garry, P.J.; Lindeman, R.D. Epidemiology of sarcopenia among the elderly in New Mexico. Am. J. Epidemiol., 1998, 147(8), 755-763.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a009520] [PMID: 9554417]
[24]
Andy, B.M.K. A language and environment for statistical computing. 2017, 10, 11-18.
[25]
Muscaritoli, M.; Fanfarillo, F.; Luzi, G.; Sirianni, M.C.; Iebba, F.; Laviano, A.; Russo, M.; Aiuti, F.; Fanelli, F.R. Impaired nutritional status in common variable immunodeficiency patients correlates with reduced levels of serum IgA and of circulating CD4+ T lymphocytes. Eur. J. Clin. Invest., 2001, 31(6), 544-549.
[http://dx.doi.org/10.1046/j.1365-2362.2001.00838.x] [PMID: 11422405]
[26]
Vieira, D.G.; Costa-Carvalho, B.T.; Hix, S.; da Silva, R.; Correia, M.S.G.; Sarni, R.O.S. Higher cardiovascular risk in common variable immunodeficiency and x-linked agammaglobulinaemia patients. Ann. Nutr. Metab., 2015, 66(4), 237-241.
[http://dx.doi.org/10.1159/000435818] [PMID: 26183722]
[27]
Kouhkan, A.; Pourpak, Z.; Moin, M.; Dorosty, A.R.; Safaralizadeh, R.; Teimorian, S.; Farhoudi, A.; Aghamohammadi, A.; Mesdaghi, M.; Kazemnejad, A. A study of malnutrition in Iranian patients with primary antibody deficiency. Iran. J. Allergy Asthma Immunol., 2004, 3(4), 189-196.
[PMID: 17301413]
[28]
Yıldız, E.; Arslan, Ş.; Çölkesen, F.; Sadi Aykan, F.; Evcen, R.; Kılınç, M.; Aytekin, G. Evaluation of malnutrition risk and nutrition status in adult patients with common variable immunodeficiency. Nutr. Clin. Pract., 2022, 37(5), 1206-1214.
[http://dx.doi.org/10.1002/ncp.10806] [PMID: 34989028]
[29]
Donini, L.M.; Busetto, L.; Bischoff, S.C.; Cederholm, T.; Ballesteros-Pomar, M.D.; Batsis, J.A.; Bauer, J.M.; Boirie, Y.; Cruz-Jentoft, A.J.; Dicker, D.; Frara, S.; Frühbeck, G.; Genton, L.; Gepner, Y.; Giustina, A.; Gonzalez, M.C.; Han, H.S.; Heymsfield, S.B.; Higashiguchi, T.; Laviano, A.; Lenzi, A.; Nyulasi, I.; Parrinello, E.; Poggiogalle, E.; Prado, C.M.; Salvador, J.; Rolland, Y.; Santini, F.; Serlie, M.J.; Shi, H.; Sieber, C.C.; Siervo, M.; Vettor, R.; Villareal, D.T.; Volkert, D.; Yu, J.; Zamboni, M.; Barazzoni, R. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin. Nutr., 2022, 41(4), 990-1000.
[http://dx.doi.org/10.1016/j.clnu.2021.11.014] [PMID: 35227529]
[30]
Gao, Q.; Mei, F.; Shang, Y.; Hu, K.; Chen, F.; Zhao, L.; Ma, B. Global prevalence of sarcopenic obesity in older adults: A systematic review and meta-analysis. Clin. Nutr., 2021, 40(7), 4633-4641.
[http://dx.doi.org/10.1016/j.clnu.2021.06.009] [PMID: 34229269]
[31]
Abete, I.; Konieczna, J.; Zulet, M.A.; Galmés-Panades, A.M.; Ibero-Baraibar, I.; Babio, N.; Estruch, R.; Vidal, J.; Toledo, E.; Razquin, C.; Bartolomé, R.; Díaz-Lopez, A.; Fiol, M.; Casas, R.; Vera, J.; Buil-Cosiales, P.; Pintó, X.; Corbella, E.; Portillo, M.P.; Paz, J.A.; Martín, V.; Daimiel, L.; Goday, A.; Rosique-Esteban, N.; Salas-Salvadó, J.; Romaguera, D.; Martínez, J.A. Association of lifestyle factors and inflammation with sarcopenic obesity: data from the PREDIMED‐Plus trial. J. Cachexia Sarcopenia Muscle, 2019, 10(5), 974-984.
[http://dx.doi.org/10.1002/jcsm.12442] [PMID: 31144432]
[32]
Karanth, S.D.; Washington, C.; Cheng, T.Y.D.; Zhou, D.; Leeuwenburgh, C.; Braithwaite, D.; Zhang, D. Inflammation in relation to sarcopenia and sarcopenic obesity among older adults living with chronic comorbidities: Results from the national health and nutrition examination survey 1999-2006. Nutrients, 2021, 13(11), 3957.
[http://dx.doi.org/10.3390/nu13113957] [PMID: 34836213]
[33]
Hel, Z.; Huijbregts, R.P.H.; Xu, J.; Nechvatalova, J.; Vlkova, M.; Litzman, J. Altered serum cytokine signature in common variable immunodeficiency. J. Clin. Immunol., 2014, 34(8), 971-978.
[http://dx.doi.org/10.1007/s10875-014-0099-z] [PMID: 25246148]
[34]
Berbers, R.M.; Drylewicz, J.; Ellerbroek, P.M.; van Montfrans, J.M.; Dalm, V.A.S.H.; van Hagen, P.M.; Keller, B.; Warnatz, K.; van de Ven, A.; van Laar, J.M.; Nierkens, S.; Leavis, H.L. Targeted proteomics reveals inflammatory pathways that classify immune dysregulation in common variable immunodeficiency. J. Clin. Immunol., 2021, 41(2), 362-373.
[http://dx.doi.org/10.1007/s10875-020-00908-1] [PMID: 33190167]
[35]
Oliveira, V.H.F.; Borsari, A.L.; Webel, A.R.; Erlandson, K.M.; Deminice, R. Sarcopenia in people living with the Human Immunodeficiency Virus: A systematic review and meta-analysis. Eur. J. Clin. Nutr., 2020, 74(7), 1009-1021.
[http://dx.doi.org/10.1038/s41430-020-0637-0] [PMID: 32341489]
[36]
de Almeida, L.L.; Ilha, T.A.S.H.; de Carvalho, J.A.M.; Stein, C.; Caeran, G.; Comim, F.V.; Moresco, R.N.; Haygert, C.J.P.; Compston, J.E.; Premaor, M.O. Sarcopenia and its association with vertebral fractures in people living with HIV. Calcif. Tissue Int., 2020, 107(3), 249-256.
[http://dx.doi.org/10.1007/s00223-020-00718-y] [PMID: 32683475]
[37]
Hegelund, M.H.; Faurholt-Jepsen, D.; Abdissa, A.; Yilma, D.; Andersen, Å.B.; Christensen, D.L.; Wells, J.C.; Friis, H.; Girma, T.; Olsen, M.F. Inflammatory markers as correlates of body composition and grip strength among adults with and without HIV: A cross-sectional study in Ethiopia. Eur. J. Clin. Nutr., 2022, 76(7), 973-978.
[http://dx.doi.org/10.1038/s41430-021-01056-4] [PMID: 35022553]
[38]
Jørgensen, S.F.; Trøseid, M.; Kummen, M.; Anmarkrud, J.A.; Michelsen, A.E.; Osnes, L.T.; Holm, K.; Høivik, M.L.; Rashidi, A.; Dahl, C.P.; Vesterhus, M.; Halvorsen, B.; Mollnes, T.E.; Berge, R.K.; Moum, B.; Lundin, K.E.A.; Fevang, B.; Ueland, T.; Karlsen, T.H.; Aukrust, P.; Hov, J.R. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol., 2016, 9(6), 1455-1465.
[http://dx.doi.org/10.1038/mi.2016.18] [PMID: 26982597]
[39]
Holm, A.M.; Aukrust, P.; Damås, J.K.; Müller, F.; Halvorsen, B.; Frøland, S.S. Abnormal interleukin-7 function in common variable immunodeficiency. Blood, 2005, 105(7), 2887-2890.
[http://dx.doi.org/10.1182/blood-2004-06-2423] [PMID: 15598813]
[40]
Barbosa, R.R.; Silva, S.P.; Silva, S.L.; Tendeiro, R.; Melo, A.C.; Pedro, E.; Barbosa, M.P.; Santos, M.C.P.; Victorino, R.M.M.; Sousa, A.E. Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. Clin. Exp. Immunol., 2012, 169(3), 263-272.
[http://dx.doi.org/10.1111/j.1365-2249.2012.04620.x] [PMID: 22861366]
[41]
AlQranei, M.S.; Senbanjo, L.T.; Aljohani, H.; Hamza, T.; Chellaiah, M.A. Lipopolysaccharide- TLR-4 axis regulates osteoclastogenesis independent of RANKL/RANK signaling. BMC Immunol., 2021, 22(1), 23.
[http://dx.doi.org/10.1186/s12865-021-00409-9] [PMID: 33765924]
[42]
van Roon, J.A.G.; Lafeber, F.P.J.G. Role of interleukin-7 in degenerative and inflammatory joint diseases. Arthritis Res. Ther., 2008, 10(2), 107.
[http://dx.doi.org/10.1186/ar2395] [PMID: 18466642]
[43]
Yokota, K.; Sato, K.; Miyazaki, T.; Aizaki, Y.; Tanaka, S.; Sekikawa, M.; Kozu, N.; Kadono, Y.; Oda, H.; Mimura, T. Characterization and function of tumor necrosis factor and interleukin‐6-induced osteoclasts in rheumatoid arthritis. Arthritis Rheumatol., 2021, 73(7), 1145-1154.
[http://dx.doi.org/10.1002/art.41666] [PMID: 33512089]
[44]
Tang, Y.; Peng, B.; Liu, J.; Liu, Z.; Xia, Y.; Geng, B. Systemic immune-inflammation index and bone mineral density in postmenopausal women: A cross-sectional study of the national health and nutrition examination survey (NHANES) 2007-2018. Front. Immunol., 2022, 13, 975400.
[http://dx.doi.org/10.3389/fimmu.2022.975400] [PMID: 36159805]
[45]
Anderson, D.M.; Maraskovsky, E.; Billingsley, W.L.; Dougall, W.C.; Tometsko, M.E.; Roux, E.R.; Teepe, M.C.; DuBose, R.F.; Cosman, D.; Galibert, L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390(6656), 175-179.
[http://dx.doi.org/10.1038/36593] [PMID: 9367155]
[46]
Hsu, H.; Lacey, D.L.; Dunstan, C.R.; Solovyev, I.; Colombero, A.; Timms, E.; Tan, H.L.; Elliott, G.; Kelley, M.J.; Sarosi, I.; Wang, L.; Xia, X.Z.; Elliott, R.; Chiu, L.; Black, T.; Scully, S.; Capparelli, C.; Morony, S.; Shimamoto, G.; Bass, M.B.; Boyle, W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci., 1999, 96(7), 3540-3545.
[http://dx.doi.org/10.1073/pnas.96.7.3540] [PMID: 10097072]
[47]
Onal, M.; Xiong, J.; Chen, X.; Thostenson, J.D.; Almeida, M.; Manolagas, S.C.; O’Brien, C.A. Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J. Biol. Chem., 2012, 287(35), 29851-29860.
[http://dx.doi.org/10.1074/jbc.M112.377945] [PMID: 22782898]
[48]
Simonet, W.S.; Lacey, D.L.; Dunstan, C.R.; Kelley, M.; Chang, M.S.; Lüthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; Colombero, A.; Tan, H.L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T.M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; Tarpley, J.; Derby, P.; Lee, R.; Boyle, W.J. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 1997, 89(2), 309-319.
[http://dx.doi.org/10.1016/S0092-8674(00)80209-3] [PMID: 9108485]
[49]
Nishida, D.; Arai, A.; Zhao, L.; Yang, M.; Nakamichi, Y.; Horibe, K.; Hosoya, A.; Kobayashi, Y.; Udagawa, N.; Mizoguchi, T. RANKL/OPG ratio regulates odontoclastogenesis in damaged dental pulp. Sci. Rep., 2021, 11(1), 4575.
[http://dx.doi.org/10.1038/s41598-021-84354-y] [PMID: 33633362]
[50]
Cohen, S.B.; Dore, R.K.; Lane, N.E.; Ory, P.A.; Peterfy, C.G.; Sharp, J.T.; van der Heijde, D.; Zhou, L.; Tsuji, W.; Newmark, R. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum., 2008, 58(5), 1299-1309.
[http://dx.doi.org/10.1002/art.23417] [PMID: 18438830]
[51]
Deodhar, A.; Dore, R.K.; Mandel, D.; Schechtman, J.; Shergy, W.; Trapp, R.; Ory, P.A.; Peterfy, C.G.; Fuerst, T.; Wang, H.; Zhou, L.; Tsuji, W.; Newmark, R. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res., 2010, 62(4), 569-574.
[http://dx.doi.org/10.1002/acr.20004] [PMID: 20391513]
[52]
Makras, P.; Petrikkos, P.; Anastasilakis, A.D.; Kolynou, A.; Katsarou, A.; Tsachouridou, O.; Metallidis, S.; Yavropoulou, M.P. Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients. Bone Rep., 2021, 15, 101128.
[http://dx.doi.org/10.1016/j.bonr.2021.101128] [PMID: 34541262]
[53]
Mok, C.C.; Ho, L.Y.; Leung, S.M.T.; Cheung, H.N.; Chen, S.P.L.; Ma, K.M. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial. Bone, 2021, 146, 115902.
[http://dx.doi.org/10.1016/j.bone.2021.115902] [PMID: 33631355]
[54]
Eller-Vainicher, C.; Palmieri, S.; Cairoli, E.; Goggi, G.; Scillitani, A.; Arosio, M.; Falchetti, A.; Chiodini, I. Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J. Am. Geriatr. Soc., 2018, 66(3), 518-524.
[http://dx.doi.org/10.1111/jgs.15250] [PMID: 29364518]
[55]
Laroche, M.; Baradat, C.; Ruyssen-Witrand, A.; Degboe, Y. Variability of Denosumab densitometric response in postmenopausal osteoporosis. Rheumatol. Int., 2018, 38(3), 461-466.
[http://dx.doi.org/10.1007/s00296-018-3929-0] [PMID: 29362876]
[56]
Gnant, M.; Pfeiler, G.; Steger, G.G.; Egle, D.; Greil, R.; Fitzal, F.; Wette, V.; Balic, M.; Haslbauer, F.; Melbinger-Zeinitzer, E.; Bjelic-Radisic, V.; Jakesz, R.; Marth, C.; Sevelda, P.; Mlineritsch, B.; Exner, R.; Fesl, C.; Frantal, S.; Singer, C.F. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): Disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol., 2019, 20(3), 339-351.
[http://dx.doi.org/10.1016/S1470-2045(18)30862-3] [PMID: 30795951]
[57]
Farlay, D.; Rizzo, S.; Dempster, D.W.; Huang, S.; Chines, A.; Brown, J.P.; Boivin, G. Bone mineral and organic properties in postmenopausal women treated with denosumab for up to 10 years. J. Bone Miner. Res., 2022, 37(5), 856-864.
[http://dx.doi.org/10.1002/jbmr.4538] [PMID: 35249242]
[58]
Ueland, T.; Frøland, S.S.; Bollerslev, J.; Aukrust, P. Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency. Eur. J. Clin. Invest., 2001, 31(1), 72-78.
[http://dx.doi.org/10.1046/j.1365-2362.2001.00768.x] [PMID: 11168441]
[59]
Titanji, K.; Vunnava, A.; Sheth, A.N.; Delille, C.; Lennox, J.L.; Sanford, S.E.; Foster, A.; Knezevic, A.; Easley, K.A.; Weitzmann, M.N.; Ofotokun, I.; Dysregulated, B. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog., 2014, 10(11), e1004497.
[http://dx.doi.org/10.1371/journal.ppat.1004497] [PMID: 25393853]
[60]
Li, G.; Lin, J.; Zhang, C.; Gao, H.; Lu, H.; Gao, X.; Zhu, R.; Li, Z.; Li, M.; Liu, Z. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Gut Microbes, 2021, 13(1), 1968257.
[http://dx.doi.org/10.1080/19490976.2021.1968257] [PMID: 34494943]
[61]
Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; Takahashi, M.; Fukuda, N.N.; Murakami, S.; Miyauchi, E.; Hino, S.; Atarashi, K.; Onawa, S.; Fujimura, Y.; Lockett, T.; Clarke, J.M.; Topping, D.L.; Tomita, M.; Hori, S.; Ohara, O.; Morita, T.; Koseki, H.; Kikuchi, J.; Honda, K.; Hase, K.; Ohno, H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 2013, 504(7480), 446-450.
[http://dx.doi.org/10.1038/nature12721] [PMID: 24226770]
[62]
Tyagi, A.M.; Yu, M.; Darby, T.M.; Vaccaro, C.; Li, J.Y.; Owens, J.A.; Hsu, E.; Adams, J.; Weitzmann, M.N.; Jones, R.M.; Pacifici, R. The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10B expression. Immunity, 2018, 49(6), 1116-1131.e7.
[http://dx.doi.org/10.1016/j.immuni.2018.10.013] [PMID: 30446387]
[63]
Fiedorová, K.; Radvanský, M.; Bosák, J. Grombiříková, H.; Němcová, E.; Králíčková, P.; Černochová, M.; Kotásková, I.; Lexa, M.; Litzman, J.; Šmajs, D.; Freiberger, T. Bacterial but not fungal gut microbiota alterations are associated with common variable immunodeficiency (CVID) phenotype. Front. Immunol., 2019, 10, 1914.
[http://dx.doi.org/10.3389/fimmu.2019.01914] [PMID: 31456808]
[64]
Macpherson, M.E.; Hov, J.R.; Ueland, T.; Dahl, T.B.; Kummen, M.; Otterdal, K.; Holm, K.; Berge, R.K.; Mollnes, T.E.; Trøseid, M.; Halvorsen, B.; Aukrust, P.; Fevang, B.; Jørgensen, S.F. Gut microbiota-dependent trimethylamine N-oxide associates with inflammation in common variable immunodeficiency. Front. Immunol., 2020, 11, 574500.
[http://dx.doi.org/10.3389/fimmu.2020.574500] [PMID: 33042155]
[65]
Panach, L.; Pineda, B.; Mifsut, D.; Tarín, J.J.; Cano, A.; García-Pérez, M.Á. The role of CD40 and CD40L in bone mineral density and in osteoporosis risk: A genetic and functional study. Bone, 2016, 83, 94-103.
[http://dx.doi.org/10.1016/j.bone.2015.11.002] [PMID: 26545336]
[66]
Forrester, J.E.; Spiegelman, D.; Woods, M.; Knox, T.A.; Fauntleroy, J.M.; Gorbach, S.L. Weight and body composition in a cohort of HIV-positive men and women. Public Health Nutr., 2001, 4(3), 743-747.
[http://dx.doi.org/10.1079/PHN200099] [PMID: 11415480]
[67]
Wrottesley, S.V.; Micklesfield, L.K.; Hamill, M.M.; Goldberg, G.R.; Prentice, A.; Pettifor, J.M.; Norris, S.A.; Feeley, A.B. Dietary intake and body composition in HIV-positive and -negative South African women. Public Health Nutr., 2014, 17(7), 1603-1613.
[http://dx.doi.org/10.1017/S1368980013001808] [PMID: 23835214]
[68]
Grant, P.M.; Kitch, D.; McComsey, G.A.; Collier, A.C.; Bartali, B.; Koletar, S.L.; Erlandson, K.M.; Lake, J.E.; Yin, M.T.; Melbourne, K.; Ha, B.; Brown, T.T. Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS, 2016, 30(18), 2805-2813.
[http://dx.doi.org/10.1097/QAD.0000000000001248] [PMID: 27662545]
[69]
Almeida, T.S.; Cortez, A.F.; Cruz, M.R.; Almeida, V.P. Predictors of sarcopenia in young hospitalized patients living with HIV. Braz. J. Infect. Dis., 2021, 25(2), 101574.
[http://dx.doi.org/10.1016/j.bjid.2021.101574] [PMID: 33861970]
[70]
Akgün, K.M.; Krishnan, S.; Butt, A.A.; Gibert, C.L.; Graber, C.J.; Huang, L.; Pisani, M.A.; Rodriguez-Barradas, M.C.; Hoo, G.W.S.; Justice, A.C.; Crothers, K.; Tate, J.P. CD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort. AIDS, 2021, 35(14), 2355-2365.
[http://dx.doi.org/10.1097/QAD.0000000000003019] [PMID: 34261095]
[71]
Cudrici, C.D.; Boulougoura, A.; Sheikh, V.; Freeman, A.; Sortino, O.; Katz, J.D.; Sereti, I.; Siegel, R.M. Characterization of autoantibodies, immunophenotype and autoimmune disease in a prospective cohort of patients with idiopathic CD4 lymphocytopenia. Clin. Immunol., 2021, 224, 108664.
[http://dx.doi.org/10.1016/j.clim.2021.108664] [PMID: 33422677]
[72]
Yarmohammadi, H.; Cunningham-Rundles, C. Idiopathic CD4 lymphocytopenia. Ann. Allergy Asthma Immunol., 2017, 119(4), 374-378.
[http://dx.doi.org/10.1016/j.anai.2017.07.021] [PMID: 28958376]
[73]
Giovannetti, A.; Pierdominici, M.; Mazzetta, F.; Marziali, M.; Renzi, C.; Mileo, A.M.; De Felice, M.; Mora, B.; Esposito, A.; Carello, R.; Pizzuti, A.; Paggi, M.G.; Paganelli, R.; Malorni, W.; Aiuti, F. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J. Immunol., 2007, 178(6), 3932-3943.
[http://dx.doi.org/10.4049/jimmunol.178.6.3932] [PMID: 17339494]
[74]
Shavit, R.; Maoz-Segal, R.; Prizinsky, S.; Haj-Yahia, S.; Offengenden, I.; Machnas-Mayan, D.; Tunisky, Y.; Iancovici-Kidon, M.; Agmon-Levin, N. Immunodeficiency (CVID and CD4 lymphopenia) is associated with a high risk of malignancy among adults with primary immune deficiency. Clin. Exp. Immunol., 2021, 204(2), 251-257.
[http://dx.doi.org/10.1111/cei.13579] [PMID: 33497464]
[75]
Malphettes, M.; Gérard, L.; Carmagnat, M.; Mouillot, G.; Vince, N.; Boutboul, D.; Bérezné, A.; Nove-Josserand, R.; Lemoing, V.; Tetu, L.; Viallard, J.F.; Bonnotte, B.; Pavic, M.; Haroche, J.; Larroche, C.; Brouet, J.C.; Fermand, J.P.; Rabian, C.; Fieschi, C.; Oksenhendler, E. Late-onset combined immune deficiency: A subset of common variable immunodeficiency with severe T cell defect. Clin. Infect. Dis., 2009, 49(9), 1329-1338.
[http://dx.doi.org/10.1086/606059] [PMID: 19807277]
[76]
Morgan, D.; Tergaonkar, V. Unraveling B cell trajectories at single cell resolution. Trends Immunol., 2022, 43(3), 210-229.
[http://dx.doi.org/10.1016/j.it.2022.01.003] [PMID: 35090788]
[77]
Matson, E.M.; Abyazi, M.L.; Bell, K.A.; Hayes, K.M.; Maglione, P.J. B cell dysregulation in common variable immunodeficiency interstitial lung disease. Front. Immunol., 2021, 11, 622114.
[http://dx.doi.org/10.3389/fimmu.2020.622114] [PMID: 33613556]
[78]
Tuttle, C.S.L.; Thang, L.A.N.; Maier, A.B. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. Ageing Res. Rev., 2020, 64, 101185.
[http://dx.doi.org/10.1016/j.arr.2020.101185] [PMID: 32992047]